We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns
Read MoreHide Full Article
On Jun 5, we issued an updated research report on Bio-Rad Laboratories, Inc. (BIO - Free Report) . The company’s solid prospects in the blood-typing market make us optimistic while its shrinking gross margin is a concern.
This California-based manufacturer and global supplier of clinical diagnostics and life-science research products has been outperforming its industry for the past six months. The stock has gained 23.9% against the industry’s 6.3% decline.
Bio-Rad exited the first quarter of 2020 with better-than-expected results. The company witnessed solid revenue growth at both operating segments. Further, strength in many of its key product lines across major geographic regions buoyed optimism.
The uptick in core PCR and Droplet Digital PCR product revenues resulted from robust demand due to coronavirus testing and related research. Further, the FDA’s emergency use authorization (EUA) for the Droplet Digital PCR COVID-19 test kit was encouraging.
Partnerships and collaborations in the time of the pandemic seem strategic for the company. It announced in March that it is providing Real-Time qPCR products to testing laboratories worldwide to screen COVID-19.
Expansion of the company’s adjusted operating margin instills optimism. A strong solvency with slight leverage, solid prospects in blood typing market and focus on international markets are other positives.
On the flip side, escalating costs and expenses are putting pressure on the bottom line. Also, foreign-exchange woes and operation in a highly competitive market raise concern.
Global macroeconomic woes stemming from the coronavirus pandemic is another headwind for the company.The stock currently carries a Zacks Rank #4 (Sell).
Key Picks
Some better-ranked stocks from the broader medical space are Aphria Inc. , Illumina, Inc. (ILMN - Free Report) and QIAGEN N.V. (QGEN - Free Report) .
Illumina’s long-term earnings growth rate is estimated at 11%. The company presently has a Zacks Rank #2.
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns
On Jun 5, we issued an updated research report on Bio-Rad Laboratories, Inc. (BIO - Free Report) . The company’s solid prospects in the blood-typing market make us optimistic while its shrinking gross margin is a concern.
This California-based manufacturer and global supplier of clinical diagnostics and life-science research products has been outperforming its industry for the past six months. The stock has gained 23.9% against the industry’s 6.3% decline.
Bio-Rad exited the first quarter of 2020 with better-than-expected results. The company witnessed solid revenue growth at both operating segments. Further, strength in many of its key product lines across major geographic regions buoyed optimism.
BioRad Laboratories, Inc. Price
BioRad Laboratories, Inc. price | BioRad Laboratories, Inc. Quote
The uptick in core PCR and Droplet Digital PCR product revenues resulted from robust demand due to coronavirus testing and related research. Further, the FDA’s emergency use authorization (EUA) for the Droplet Digital PCR COVID-19 test kit was encouraging.
Partnerships and collaborations in the time of the pandemic seem strategic for the company. It announced in March that it is providing Real-Time qPCR products to testing laboratories worldwide to screen COVID-19.
Expansion of the company’s adjusted operating margin instills optimism. A strong solvency with slight leverage, solid prospects in blood typing market and focus on international markets are other positives.
On the flip side, escalating costs and expenses are putting pressure on the bottom line. Also, foreign-exchange woes and operation in a highly competitive market raise concern.
Global macroeconomic woes stemming from the coronavirus pandemic is another headwind for the company.The stock currently carries a Zacks Rank #4 (Sell).
Key Picks
Some better-ranked stocks from the broader medical space are Aphria Inc. , Illumina, Inc. (ILMN - Free Report) and QIAGEN N.V. (QGEN - Free Report) .
Aphria’s long-term earnings growth rate is projected to be 24.6%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Illumina’s long-term earnings growth rate is estimated at 11%. The company presently has a Zacks Rank #2.
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>